Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...

Me (ME), the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring “strategic ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...